The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a significant substantial decrease in body size and improve metabolic function,… Read More